Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | BMC Musculoskeletal Disorders

Figure 3

From: Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study

Figure 3

Association of Teriparatide Persistence and 12-Month Fracture Risk* . Likelihood Ratio: (Χ2 = 54.83, 15 d.f. p < 0.0001), c statistic: 0.669. * Odds ratio and 95% confidence interval of experiencing a fracture during 12-month follow-up period based on persistence and adjusted for age, gender, race/ethnicity, pre-period fractures, comorbidity, geographic region, and pre-period OP medication use. Discontinue teriparatide = non-persistent with teriparatide.

Back to article page